Cheapest Tirzepatide and Semaglutide: Compounded vs Branded Cost

As of 3 October 2026, the cheapest legal tirzepatide without insurance is Lilly’s own self-pay price. A Zepbound vial or KwikPen costs $299 a month at the 2.5 mg starting dose. The cheapest semaglutide is the Wegovy or Ozempic pill at $149 a month for the 1.5 mg starting dose. The Wegovy pen costs $349 a month after two $199 introductory fills.

Compounded versions are priced by each clinic or pharmacy, so they are not in the table. Every price below comes from the manufacturer’s own page or a government listing, checked on 3 October 2026.

Tirzepatide and semaglutide prices without insurance

Tirzepatide (Zepbound, Mounjaro), Eli Lilly self-pay prices, one month = 28 days:

The $449 price applies to the first fill at 7.5 mg or above and to refills within 45 days. Lilly’s savings page states it for the KwikPen, and TrumpRx lists the same $449 for vials. Mounjaro is approved for type 2 diabetes, not weight loss.

Semaglutide (Wegovy, Ozempic), Novo Nordisk self-pay prices:

Ozempic is approved for type 2 diabetes. Wegovy is the semaglutide brand approved for weight management. Novo will cut the list price of Wegovy 2.4 mg, the 25 mg Wegovy pill and Ozempic to $675 on 1 January 2027. It says self-pay prices are not affected.

Every product above needs a prescription. For how to fill one, see tirzepatide online and semaglutide online.

Our GLP-1 cash price tracker lists every price above with its source, and records any change each time we recheck.

With insurance or Medicare

• Commercial insurance that covers the drug. Lilly’s Zepbound card brings a covered single-dose pen fill to as little as $25, with savings capped at $100 a month and $1,300 a year. The Mounjaro card works the same way with a $150 monthly cap. Novo’s offer brings Wegovy or Ozempic to as little as $25, with savings capped at $100 a month. Lilly’s cards expire on 31 December 2026.
• Government plans. The manufacturer cards exclude Medicare, Medicaid and other government programmes.
• Medicare Part D. From 1 July 2026, the Medicare GLP-1 Bridge covers Foundayo, Wegovy (pen or pill) and the Zepbound KwikPen for weight management, for a $50 monthly copay. Zepbound vials and single-dose pens are not covered, and eligibility rules apply.

For how many GLP-1 prescriptions Medicaid and Medicare pay for, by state and by year, see GLP-1 prescriptions in Medicaid and Medicare.

Is compounded tirzepatide or semaglutide cheaper?

Sometimes. Compare any compounded quote with the manufacturer prices above. FDA has also narrowed when compounding these drugs is lawful.

FDA’s shortage-era enforcement discretion, for both 503A pharmacies and 503B outsourcing facilities, had ended by 19 March 2025 for tirzepatide and by 22 May 2025 for semaglutide. Neither drug is on FDA’s shortage list or its 503B bulks list, so outsourcing facilities may not compound them from bulk ingredients.

FDA went further in 2026:

• 6 February: it said it intends to restrict the GLP-1 ingredients used in non-approved compounded drugs that are mass-marketed as alternatives to approved ones.
• 3 March: it announced warning letters to 30 telehealth companies over claims that compounded products are the same as approved drugs.

Compounded drugs are not FDA-approved, so FDA does not review their safety, effectiveness or quality before sale.

What structurally separates the two prices

Branded semaglutide and tirzepatide went through full FDA review: manufacturing controls, clinical trials and ongoing safety monitoring. That cost sits inside one manufacturer’s price.

Compounded product is made under section 503A (a licensed pharmacy or doctor, for a named patient) or 503B (an outsourcing facility). Both are exempt from premarket approval by design, which is one real reason a compounded product can cost less.

Within compounded product, price also moves with:

• Formulation and dose. A compounded product can come in a different strength or combination, such as with added vitamin B12, and its price follows the pharmacy’s own preparation.
• Business model. Subscription clinics, direct-to-pharmacy dispensing and traditional compounding pharmacies carry different costs, such as consult fees, shipping and cold packaging, inside or outside the quoted price.
• Insurance. Compounded product is usually paid in cash. Approved, on-label prescriptions can be covered by insurance or a manufacturer card.

FDA’s telehealth red flags

FDA publishes a list of warning signs for online and telehealth sellers of GLP-1 drugs. A seller showing any of these should raise questions:

• Claims that the compounded drug “is the same as” an FDA-approved drug.
• Deep discounts, or a price that seems too good to be true.
• Medicine that looks different from what you received before, or arrives in damaged packaging or without instructions.
• No screening and prescription by a licensed doctor before dispensing.
• No licensed doctor available to answer questions afterwards.
• Spelling errors on the label, or an incorrect pharmacy address.
• A pharmacy name on the label that looks fraudulent.

A low price on its own proves nothing. Combined with any of the other signs, it is a reason to verify the pharmacy before paying.

Why a low price cannot come from unlimited volume

FDA’s compounding rules limit how far a lawful 503A pharmacy can compete on price. FDA treats a compounded product as “essentially a copy” of an approved drug when it has the same active ingredient by the same route. The strength can be the same, similar or easily substitutable. The exception is a prescriber documenting a significant difference for that patient.

FDA gives an example: semaglutide combined with vitamin B12 can still count as a copy when both amounts are within 10% of the approved products’ strengths. FDA says it does not intend to act against a pharmacy filling four or fewer such prescriptions a month. A cheap price built on high volume of a copy sits outside that. See compounded vs branded semaglutide for the full rule.

FDA also flags quality problems:

• Different active ingredients. It states that semaglutide sodium and semaglutide acetate, which some compounders have used, are different active ingredients from the one in the approved drugs.
• Counterfeits and mislabelling. It reports counterfeit Ozempic, and compounded semaglutide and tirzepatide labelled with pharmacies that did not make them.
• Warm deliveries. It reports compounded GLP-1s arriving warm or with inadequate ice packs.

As of 31 May 2026, FDA had received 990 adverse event reports tied to compounded semaglutide and more than 730 tied to compounded tirzepatide. Pharmacies that are not outsourcing facilities do not have to report adverse events, so FDA says these are likely underreported.

Questions worth asking before paying

A legitimate pharmacy or clinic should answer all of these without hesitation:

• What is the exact active ingredient and salt form, in writing?
• Is it compounded under 503A or 503B, and by which licensed facility?
• Does the quoted price include the consult, or is that billed separately?
• What happens to the price, and to access to a prescriber, after the first fill?
• How is it shipped and stored in transit, and what happens if it arrives warm?

Related

• Tirzepatide online: getting Zepbound legally
• Semaglutide online: getting Wegovy or Ozempic legally
• Best GLP-1 for weight loss: the approved options compared
• Compounded vs branded semaglutide (and tirzepatide)
• Category 1, Category 2 and the 503A bulks list, explained
• Peptide telehealth: how legal prescribing works
• Semaglutide: the approved label
• Tirzepatide: the approved label

Common questions

What is the cheapest way to get tirzepatide?

With commercial insurance that covers Zepbound, Lilly's savings card can bring a fill to $25, with savings capped at $100 a month and $1,300 a year. Without insurance, as of 3 October 2026, Lilly's self-pay price for a Zepbound vial or KwikPen is $299 a month at 2.5 mg and $399 at 5 mg. From 7.5 mg it is $449 with refills within 45 days. Eligible Medicare Part D members can get the Zepbound KwikPen for weight management for $50 a month through the Medicare GLP-1 Bridge.

How much is tirzepatide without insurance?

As of 3 October 2026, Lilly charges self-pay patients $299 to $699 a month for a Zepbound vial or KwikPen, depending on dose. The price is $449 for 7.5 mg to 15 mg when each refill comes within 45 days. Mounjaro, the diabetes brand, is listed at $499 for a one-month fill on TrumpRx. The Zepbound single-dose pen is $499 with Lilly's card only for people whose commercial insurance does not cover it.

How much is 3 months of tirzepatide?

At Lilly's self-pay prices on 3 October 2026, three monthly fills on the usual first dose steps (2.5 mg, then 5 mg, then 7.5 mg) cost $1,147. That is $299, $399 and $449. Lilly defines a month as 28 days, and the prescriber decides when to raise the dose.

How do you get tirzepatide for $25 a month?

Only with commercial insurance that covers it. Lilly's Zepbound savings card lowers a covered single-dose pen fill to as little as $25, with savings capped at $100 a month and $1,300 a year. The Mounjaro card works the same way with a $150 monthly cap. Both cards expire on 31 December 2026 and exclude Medicare, Medicaid and other government plans.

What is the average cost of tirzepatide in the US?

I found no published average of what patients actually pay, and Lilly says it does not yet have that data for Mounjaro. Lilly's list price is $499 to $1,086.37 per fill for Zepbound and $1,112.16 per fill for Mounjaro, but most insured patients do not pay list price. Self-pay patients pay Lilly $299 to $699 a month for Zepbound vials or KwikPens, as of 3 October 2026.

Is there a generic Zepbound?

I found none. FDA's Drugs@FDA database lists two tirzepatide applications, both held by Eli Lilly: Mounjaro and Zepbound (checked 3 October 2026). Compounded tirzepatide is not a generic. It is not FDA-approved, and FDA says sellers may not call compounded GLP-1 drugs generic versions of approved ones.

How much do semaglutide pills cost per month?

As of 3 October 2026, Novo Nordisk's self-pay price for a 30-tablet bottle of the Wegovy pill is $149 a month at 1.5 mg. It is $199 at 4 mg and $299 at 9 mg or 25 mg. The Ozempic pill, approved for type 2 diabetes, is $149, $199 and $299 for 1.5 mg, 4 mg and 9 mg.

Are there semaglutide discounts or coupons?

Yes, from Novo Nordisk. With commercial insurance that covers Wegovy or Ozempic, its savings offer brings the cost to as little as $25 a month, with savings capped at $100 a month. Without insurance, its self-pay offers include $199 for the first two months of the lowest pen doses for new patients through 31 December 2026. Eligible Medicare Part D members can get Wegovy for $50 a month through the Medicare GLP-1 Bridge.

What is the new price of semaglutide?

Novo Nordisk announced on 24 February 2026 a list-price cut to $675 from 1 January 2027 for Wegovy 2.4 mg, the Wegovy 25 mg pill and Ozempic. It said self-pay prices are not affected. Today's self-pay prices are $149 to $299 a month for the Wegovy pill and $349 for the Wegovy pen after two $199 introductory fills, as of 3 October 2026.

What is the cheapest GLP-1 drug I can buy without insurance?

At manufacturer self-pay prices on 3 October 2026, the lowest is $149 a month, for starting doses. These are the Wegovy pill 1.5 mg, Foundayo 0.8 mg and 2.5 mg, and the Ozempic pill 1.5 mg. The Foundayo 2.5 mg price is a temporary cut through 31 December 2026. The Ozempic pill is approved for type 2 diabetes. Higher doses cost more. Every one of them needs a prescription.

Is compounded tirzepatide cheaper than Zepbound?

Sometimes, but compare any quote with Lilly's own self-pay price of $299 to $449 a month for Zepbound vials and KwikPens with refills within 45 days. Compounded tirzepatide is not FDA-approved. FDA ended its shortage-era allowance for compounding it in 2025. In February 2026 it said it intends to restrict the GLP-1 ingredients used in mass-marketed compounded copies.

Does a low price mean a compounded product is fake or unsafe?

Not on its own. FDA lists deep discounts or a price that seems too good to be true as one of several telehealth red flags, alongside no doctor screening, damaged packaging and label errors. A low price combined with any of those other signs is a reason to verify the pharmacy before paying.

Can a compounding pharmacy legally undercut the branded price at any volume?

No. FDA treats a compounded product as essentially a copy of an approved drug when it has the same active ingredient in a similar strength by the same route. The exception is a prescriber documenting a significant difference for that patient. FDA says it does not intend to act against a pharmacy filling four or fewer such prescriptions a month. Pricing built on high volume of a copy sits outside that.

Which online provider offers the cheapest tirzepatide?

I do not rank providers. For branded tirzepatide, Lilly's own self-pay price is the reference point. As of 3 October 2026 it is $299 to $449 a month for Zepbound vials and KwikPens with refills within 45 days. Ask any clinic whether its quote includes the consult, and check that a licensed clinician screens you and a named state-licensed pharmacy fills the prescription. Tirzepatide sold online as a research chemical is not a lawful route at any price.

References (17 sources)

Show

Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.

1. 1.Lilly pricing information for Zepbound: list price range per fill and direct-to-patient self-pay prices by dose for vials and KwikPens (checked 3 October 2026).- Eli Lilly and Companyother
2. 2.Zepbound savings and self-pay page: $449 KwikPen purchase offer with refills within 45 days, regular prices, savings card terms and Medicare GLP-1 Bridge cost (checked 3 October 2026).- Eli Lilly and Companyother
3. 3.Lilly pricing information for Mounjaro: list price per fill (checked 3 October 2026).- Eli Lilly and Companyother
4. 4.Mounjaro savings and coverage page: savings card terms for covered and non-covered commercial insurance (checked 3 October 2026).- Eli Lilly and Companyother
5. 5.TrumpRx listing for Mounjaro single-dose pens: $499 out-of-pocket price at every strength, against a $1,112.16 list price, orders through LillyDirect (checked 3 October 2026).- TrumpRx.gov (US government)database
6. 6.TrumpRx listing for Zepbound vials: per-strength self-pay prices, including $449 for 7.5 mg to 15 mg with refills within 45 days (checked 3 October 2026).- TrumpRx.gov (US government)database
7. 7.Foundayo coverage and savings page: regular self-pay prices by dose and temporary reductions through 31 December 2026 (checked 3 October 2026).- Eli Lilly and Companyother
8. 8.What to pay for Wegovy: self-pay prices for the Wegovy pill, pen and HD pen, the intro offer, the commercial savings offer and the Medicare GLP-1 Bridge (checked 3 October 2026).- Novo Nordisk Inc.other
9. 9.Save on Ozempic: self-pay prices for the Ozempic pen and pill and the commercial savings offer (checked 3 October 2026).- Novo Nordisk Inc.other
10. 10.Novo Nordisk news release, 24 February 2026: list price of Wegovy, Ozempic and Rybelsus to fall to $675 from 1 January 2027; self-pay prices not affected.- Novo Nordisknews
11. 11.Medicare.gov - weight loss drugs: the Medicare GLP-1 Bridge covers Foundayo, Wegovy and the Zepbound KwikPen from 1 July 2026, with a $50 monthly copay.- Centers for Medicare & Medicaid Servicesregulatory
12. 12.openFDA Drugs@FDA query for tirzepatide: two applications, both Eli Lilly NDAs (Mounjaro and Zepbound), checked 3 October 2026.- US Food and Drug Administrationdatabase
13. 13.FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (updated 1 October 2026): telehealth red flags, salt forms, warm deliveries and adverse event counts to 31 May 2026.- US Food and Drug Administrationregulatory
14. 14.FDA - FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (updated 1 April 2026): essentially-a-copy test, the B12 example, four prescriptions a month, and 503B limits.- US Food and Drug Administrationregulatory
15. 15.FDA news release, 6 February 2026: FDA intends to restrict GLP-1 ingredients used in mass-marketed non-approved compounded drugs, and limits marketing claims.- US Food and Drug Administrationregulatory
16. 16.FDA news release, 3 March 2026: warning letters to 30 telehealth companies over claims of sameness and obscured sourcing for compounded GLP-1 drugs.- US Food and Drug Administrationregulatory
17. 17.FDA - FD&C Act Provisions that Apply to Human Drug Compounding, on what compounding under Section 503A and Section 503B means.- US Food and Drug Administrationregulatory

Keep reading

Related guides

All guides →

• cjc-1295 vs sermorelinCJC-1295 vs Sermorelin: One Sequence, Two HistoriesBoth are built on the first 29 amino acids of GHRH. One was approved for children and later withdrawn by its sponsor; the other never got past Phase 2.7 min readRead guide→
• compounded vs branded semaglutideCompounded Semaglutide and Compounded Tirzepatide vs. Branded: What DiffersWhat legally differs between FDA-approved branded semaglutide/tirzepatide and compounded semaglutide or compounded tirzepatide from a pharmacy.5 min readRead guide→
• semaglutide units chartCompounded Semaglutide Dosage Chart: Units for Each Label DoseUnits to draw for each FDA label dose of semaglutide, by compounded vial strength - not a dose recommendation. Compounded semaglutide is not FDA-approved.3 min readRead guide→
• compounded tirzepatide dosage chartCompounded Tirzepatide Dosage Chart in UnitsUnits to draw for each FDA label dose of tirzepatide, by compounded vial strength - not a dose recommendation. Compounded tirzepatide is not FDA-approved.3 min readRead guide→
• hgh peptidesHGH Peptides vs Recombinant HGH: Two Different Drugs, Compared'HGH peptides' (GH secretagogues) prompt the pituitary to release growth hormone. Recombinant HGH is that hormone itself, FDA-approved for defined deficiencies only.7 min readRead guide→
• ipamorelin vs sermorelinIpamorelin vs Sermorelin: Two Receptors, Two HistoriesBoth release growth hormone from the pituitary, through different receptors. One was approved for children; the other stopped at Phase 2 for lack of efficacy.5 min readRead guide→